A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

The last several years have witnessed exciting progress in the development of immunotherapy for the treatment of cancer. This has been due in great part to the development of so-called checkpoint blockade. That is, antibodies that block inhibitory receptors such as CTLA-4 and PD-1 and thus unleash a...

Descripción completa

Detalles Bibliográficos
Autores principales: Leone, Robert D., Lo, Ying-Chun, Powell, Jonathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415113/
https://www.ncbi.nlm.nih.gov/pubmed/25941561
http://dx.doi.org/10.1016/j.csbj.2015.03.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415113/
https://www.ncbi.nlm.nih.gov/pubmed/25941561
http://dx.doi.org/10.1016/j.csbj.2015.03.008

Ejemplares similares